Effect of dermatan sulphate on a C57-mouse model of pulmonary fibrosis. Issue 6 (June 2019)

• Record Type: Journal Article
• Authors: Xu, Jianfeng; Li, Wei; Xu, Shufen; Gao, Weiyang; Yu, Zhenyu
• Is Part Of: Journal of international medical research. Volume 47:Issue 6(2019)
• Page Start: 2655
• Page End: 2665
• Publication Date: 2019-06
• Subjects: Dermatan sulphate -- pulmonary fibrosis -- bleomycin; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060519842048
• Languages: English
• ISSNs: 0300-0605

Abstract

Objective: To test the antifibrotic effect of dermatan sulphate in a bleomycin-induced mouse model of pulmonary fibrosis. Methods: C57 mice were randomly divided into four experimental groups: saline-treated control group, bleomycin-induced fibrosis group, prednisolone acetate group and dermatan sulphate group. Lungs were assessed using the lung index, and the extent of interstitial fibrosis was graded using histopathological observation of haematoxylin & eosin-stained lung tissue. Lung tissue hydroxyproline levels and blood fibrinogen levels were measured using a hydroxyproline colorimetric kit and the Clauss fibrinogen assay, respectively. Tissue-type plasminogen activator (tPA) was measured using a chromogenic tPA assay kit. Results: Lung index values were significantly lower in the dermatan sulphate group versus the fibrosis group. Histopathological analyses revealed that dermatan sulphate treatment ameliorated the increased inflammatory cell infiltration, and attenuated the reduction in interstitial thickening, associated with bleomycin-induced fibrosis. Hydroxyproline and fibrinogen levels were decreased in the dermatan sulphate group versus the fibrosis model group. Dermatan sulphate treatment was associated with increased tPA levels versus controls and the fibrosis group. Conclusions: Damage associated with bleomycin-induced pulmonary fibrosis was alleviated by dermatan sulphate.